Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis PR Newswire Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with con...
JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS) PR Newswire Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in signific...
UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting PR Newswire Scientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological disease...
FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) PR Newswire FINTEPLA ® has demonstrated efficacy in the most difficult-to-treat seizure types, 1 ,2 including drop se...
New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting PR Newswire Eleven abstracts highlight new data on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis...
UCB (OTCPK:UCBJF) has completed its acquisition of Zogenix (ZGNX), a deal valued at up to $1.9B. The Belgian company acquired Zogenix (ZGNX) for $26 per share plus a milestone-based contingent value right for a potential cash payment of $2 per share. As a result, Zogenix (ZGNX) was delis...
The following slide deck was published by UCB SA in conjunction with their 2021 Q4 earnings call. For further details see: UCB SA 2021 Q4 - Results - Earnings Call Presentation
UCB SA (UCBJF) Q4 2021 Earnings Conference Call February 24, 2022, 8:00 AM ET Company Participants Jean-Christophe Tellier – Chief Executive Officer Sandrine Dufour – Chief Financial Officer Iris Löw-Friedrich – Chief Medical Officer Antje Witte – Vice Preside...
UCB SA press release (OTCPK:UCBJF): FY Non-GAAP EPS of €6.49. Revenue of €5.78B (+8.0% Y/Y). For further details see: UCB SA Non-GAAP EPS of €6.49, revenue of €5.78B
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results - Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis - The results show...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price! PR Newswire Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi announce the fu...
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...